JP2014515747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515747A5 JP2014515747A5 JP2014504346A JP2014504346A JP2014515747A5 JP 2014515747 A5 JP2014515747 A5 JP 2014515747A5 JP 2014504346 A JP2014504346 A JP 2014504346A JP 2014504346 A JP2014504346 A JP 2014504346A JP 2014515747 A5 JP2014515747 A5 JP 2014515747A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- seq
- oxytocin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 14
- 102400000050 Oxytocin Human genes 0.000 claims 13
- 101800000989 Oxytocin Proteins 0.000 claims 13
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 13
- 229960001723 oxytocin Drugs 0.000 claims 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 229920003086 cellulose ether Polymers 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 8
- 239000005711 Benzoic acid Substances 0.000 claims 4
- 235000010233 benzoic acid Nutrition 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108010004977 Vasopressins Proteins 0.000 claims 3
- 241000024188 Andala Species 0.000 claims 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000003893 lactate salts Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475471P | 2011-04-14 | 2011-04-14 | |
| SE1150324A SE536091C2 (sv) | 2011-04-14 | 2011-04-14 | Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter |
| US61/475,471 | 2011-04-14 | ||
| SE1150324-0 | 2011-04-14 | ||
| PCT/EP2012/056813 WO2012140216A1 (en) | 2011-04-14 | 2012-04-13 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515747A JP2014515747A (ja) | 2014-07-03 |
| JP2014515747A5 true JP2014515747A5 (cg-RX-API-DMAC7.html) | 2015-05-28 |
| JP5993442B2 JP5993442B2 (ja) | 2016-09-14 |
Family
ID=47008851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504346A Expired - Fee Related JP5993442B2 (ja) | 2011-04-14 | 2012-04-13 | 医薬組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9034821B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2696882B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5993442B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101940341B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103596582B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012241805B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013026153A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2832664C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2696882T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2535521T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL228821A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2696882T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2605288C2 (cg-RX-API-DMAC7.html) |
| SE (1) | SE536091C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG194074A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012140216A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201308157B (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014057092A1 (en) * | 2012-10-12 | 2014-04-17 | Pep-Tonic Medical Ab | Novel use of a composition comprising oxytocin |
| CN107847552B (zh) | 2015-01-07 | 2022-07-01 | 三叉神经股份公司 | 含镁的催产素制剂和使用方法 |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US10849978B2 (en) | 2015-10-30 | 2020-12-01 | Teijin Pharma Limited | Pharmaceutical composition for administration to nasal mucosa |
| EP4541348A3 (en) | 2016-04-12 | 2025-06-04 | Tonix Pharma Limited | Magnesium-containing oxytocin formulations and methods of use |
| SE1750680A1 (en) * | 2017-05-30 | 2018-12-01 | Peptonic Medical Ab | Composition for treating or preventing climacteric disorders |
| EP3852723B1 (en) * | 2018-09-20 | 2025-11-05 | ACADIA Pharmaceuticals Inc. | Stable intranasal formulations of carbetocin |
| CN110169377B (zh) * | 2019-06-27 | 2021-09-14 | 浙江海洋大学 | 黄姑鱼的人工催产受精方法 |
| SE547797C2 (en) | 2023-09-25 | 2025-11-25 | Letavis Ab | Stimulation of plant germination |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3076797A (en) | 1957-07-22 | 1963-02-05 | Roussel Uclaf | Process of producing oxytocin and intermediates obtained thereby |
| US2938991A (en) | 1957-10-01 | 1960-05-31 | Candace Inc | Electric mattress pad |
| JPS61126014A (ja) * | 1984-11-22 | 1986-06-13 | Teijin Ltd | 経鼻投与用水性液剤 |
| SE466134B (sv) | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner |
| JP3179538B2 (ja) * | 1990-12-11 | 2001-06-25 | ノバルティス アクチエンゲゼルシャフト | 安定なヒトカルシトニンの水性溶液 |
| GB9326354D0 (en) | 1993-12-23 | 1994-02-23 | British Aerospace | Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness |
| SE9400918L (sv) * | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| US5833647A (en) * | 1995-10-10 | 1998-11-10 | The Penn State Research Foundation | Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery |
| CA2247191C (en) | 1996-02-27 | 2005-01-04 | Teijin Limited | Powdery composition for nasal administration |
| SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
| SE9701162D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
| SE9701184D0 (sv) | 1997-04-01 | 1997-04-01 | Karolinska Innovations Ab | Substanser för att åstadkomma preferens och skapa acceptans |
| SE9803272D0 (sv) * | 1998-09-25 | 1998-09-25 | Kerstin Uvnaes Moberg | A drug for cell regeneration |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| SE0001440D0 (sv) * | 2000-04-18 | 2000-04-18 | Entretech Medical Ab | A drug against climacteric disorders |
| SE0100684D0 (sv) * | 2001-02-28 | 2001-02-28 | Kerstin Uvnaes Moberg | New subject-matter |
| SE0102184D0 (sv) | 2001-06-19 | 2001-06-19 | Uvnaes Moberg Kerstin | New subject-matter |
| SE0102910D0 (sv) | 2001-08-31 | 2001-08-31 | Moberg Kerstin Uvnaes | New use |
| JO2492B1 (en) * | 2003-04-28 | 2009-10-05 | شيرينج ايه جي | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients |
| US7884076B2 (en) * | 2003-11-06 | 2011-02-08 | The Trustees Of Columbia University In The City Of New York | Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders |
| EP1765293B1 (en) * | 2004-06-24 | 2014-10-01 | Idexx Laboratories, Inc. | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
-
2011
- 2011-04-14 SE SE1150324A patent/SE536091C2/sv not_active IP Right Cessation
-
2012
- 2012-04-13 BR BR112013026153A patent/BR112013026153A2/pt not_active Application Discontinuation
- 2012-04-13 EP EP12715932.5A patent/EP2696882B1/en active Active
- 2012-04-13 SG SG2013074133A patent/SG194074A1/en unknown
- 2012-04-13 ES ES12715932.5T patent/ES2535521T3/es active Active
- 2012-04-13 CA CA2832664A patent/CA2832664C/en active Active
- 2012-04-13 DK DK12715932T patent/DK2696882T3/en active
- 2012-04-13 RU RU2013147739/15A patent/RU2605288C2/ru active
- 2012-04-13 KR KR1020137029608A patent/KR101940341B1/ko not_active Expired - Fee Related
- 2012-04-13 AU AU2012241805A patent/AU2012241805B2/en not_active Ceased
- 2012-04-13 US US14/111,072 patent/US9034821B2/en active Active
- 2012-04-13 PL PL12715932T patent/PL2696882T3/pl unknown
- 2012-04-13 WO PCT/EP2012/056813 patent/WO2012140216A1/en not_active Ceased
- 2012-04-13 CN CN201280027310.1A patent/CN103596582B/zh not_active Expired - Fee Related
- 2012-04-13 JP JP2014504346A patent/JP5993442B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-10 IL IL228821A patent/IL228821A/en active IP Right Grant
- 2013-10-31 ZA ZA2013/08157A patent/ZA201308157B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515747A5 (cg-RX-API-DMAC7.html) | ||
| JP2023017854A (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| RU2013147739A (ru) | Фармацевтическая композиция | |
| JP5847793B2 (ja) | Ｖｉｐ断片および使用の方法 | |
| US20230107222A1 (en) | Engineered antimicrobial amphiphilic peptides and methods of use | |
| KR101671406B1 (ko) | 신장 장애 치료용 조성물 및 방법 | |
| JP2014012667A (ja) | ペプチドおよびその使用 | |
| JP7280619B2 (ja) | ペプチド組成物 | |
| JP2019214610A (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ | |
| CN102068685A (zh) | 一种特利加压素制剂及其制备方法 | |
| RU2012155711A (ru) | Жидкий назальный спрей, содержащий налтрексон в низкой дозе | |
| JPWO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| US20240139279A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2010517987A (ja) | 塩基性ペプチド及びその複合型抗細菌−抗真菌剤としての使用 | |
| WO2019178274A1 (en) | Treatment of implants with engineered antimicrobial amphiphilic peptides | |
| WO2019095685A1 (zh) | 一种功能多肽及其在制备防治肺纤维化药物中的应用 | |
| Yu et al. | The novel peptide PACAP-TAT with enhanced traversing ability attenuates the severe lung injury induced by repeated smoke inhalation | |
| CA3229783A1 (en) | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions | |
| EP2908840A1 (en) | Novel use of a composition comprising oxytocin | |
| WO2017149098A1 (en) | Fusion respiratory syncytial virus inhibitors and use thereof | |
| JP2020518658A (ja) | 癌治療用ペプチド | |
| JPWO2018038168A1 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
| AU2020385059A1 (en) | Polypeptides related to HMGB1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof | |
| US20240115654A1 (en) | Intravenous administration of engineered antimicrobial amphiphilic peptides | |
| Rennard et al. | Efficacy and Safety of the Novel, Long-Acting Antimuscarinic, Aclidinium Bromide, in COPD Patients in a Phase III Study: ACCLAIM/COPD II. |